Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia

Blood

Volumn 92, Issue 5, 1998, Pages 1541-1548

  Tura, Sante ^a   Rosti, Gianantonio ^a   De Vivo, Antonio ^a   Bonifazi, Francesca ^a   Fiacchini, Mauro ^a   Baccarani, Michele ^b,e   Russo, Domenico ^b   Fanin, Renato ^b   Zuffa, Eliana ^c   Montefusco, Enrico ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c Ravenna Hospital

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; HYDROXYUREA; RECOMBINANT ALPHA2A INTERFERON;

ALLERGIC REACTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FATIGUE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; ITALY; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PAIN; PRIORITY JOURNAL; SKIN MANIFESTATION;

EID: 0342541022     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1541     Document Type: Article

References (36)

1. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689, 1983
2. a in chronic myelogenous leukemia. N Engl J Med 314:1065, 1986
3. + chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 77:204, 1992
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 12:820, 1994
5. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532, 1991
6. Kloke O, Niederle N, Qiu JY, Wandl T, Moritz M, Nagel-Hiemke M, Hawig I, Opalka B, Seeber S, Becher R: Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 83:399, 1993
7. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, Lebeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583. Blood 82:2975, 1993
8. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
9. Allan NC, Richards SM, Shepherd PCA on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
10. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hiroshima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K, the Kouseisho Leukemia Study Group: A randomized trial comparing Interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995
11. The German and Italian Chronic Myeloid Leukemia Study Groups Writing Committee (J. Hasford, M. Baccarani, R. Hehlmann, H. Ansari, S. Tura, E. Zuffa): Interferon-α and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German Chronic Myeloid Leukemia Trials with Interferon-α. Blood 87:5384, 1996
12. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferon-α therapy. Ann Intern Med 122:254, 1995
13. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789, 1984
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:475, 1958
15. Cox DR: The analysis of binary data. London, UK, Chapman & Half, 1970
16. Bilhou-Nabéra C, Marit G, Gharbi MJ, Salzes S, Mahon FX, Broustet A, Reiffers J, Bernard P: Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: Minimal residual disease follow-up. Leukemia 9:2067, 1995
17. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA: Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79:1920, 1992
18. Hochhaus A, Lin F, Reiter A, Skladny H, Van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP: Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 91:126, 1995
19. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069, 1996
20. Schofield JR, Robinson WA, Murphy JR, Rovira DK: Low doses of Interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736, 1994
21. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M: Interferon-α therapy for chronic myelogenous leukemia. Am J Med 99:402, 1995
22. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J, for the French Chronic Myeloid Leukemia Study Group: Interferon alfa-2b combined with Cytarabine versus Interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223, 1997
23. Butturini A, Keating A, Goldman J, Gale RP: Autotransplants in chronic myelogenous leukaemia: Strategies and results. Lancet 335: 1255, 1990
24. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486, 1994
25. Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, Benvenuto F, Valbonesi M, Carlier P, Vimercati R, Prencipe E, Gatti AM, Ferrara RA, Incagliato M, Florio G, Frassoni F: High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 17:201, 1996
26. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 87:4770, 1995
27. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leukemia Lymphoma 11:277, 1993 (suppl 1)
28. Clift RA, Appelbaum FR, Thomas Ed: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993
29. Beelen DW, Graeven U, Elmaagacli A, Niederle N, Kloke O, Opalka B, Schaefer UW: Prolonged administration of Interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981, 1995
30. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055, 1993
31. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFNα versus chemotherapy: No significant adverse effect of prolonged IFNα administration. Proc 37th Annual Meeting ASH. Blood 86:94a, 1995 (abstr 363, suppl 1)
32. Rosti G, Zuffa E, Bandini G, Martinelli G, Testoni N, Tura S: α-interferon for CML patients before allogeneic BMT: Any influence on transplant outcome? Proc 22nd Annual Meeting EBMT. Bone Marrow Transplant 17:561, 1996 (abstr 288, suppl 1)
33. Horowitz MM, Giralt S, Szydlo R, Goldman J, Veum-Stone J for the International Bone Marrow Transplant Registry: Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase. Proc 38th Annual Meeting ASH. Blood 88:682a, 1996 (abstr 2716, suppl 1)
34. McGlave P, Kollman C, Shu XO, Anasetti C, Nademanee A, Champlin R, Antin J, Kernan N, King R: The first 1,000 unrelated donor transplants for CML: Lessons from the National Marrow Donor Program (NMDP) experience. Proc 38th Annual Meeting ASH. Blood 88:483a, 1996 (abstr 1922, suppl 1)
35. Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Hegland J, Kollman C, Weeks JC, Antin JH: A decision analysis of unrelated donor transplantation (URD BMT) for CML. Proc 38th Annual Meeting ASH. Blood 88:484a, 1996 (abstr 1923, suppl 1)
36. Tura S: Monitoring the effect of allogeneic bone marrow transplantation (BMT) and α-interferon (IFN) in chronic myeloid leukemia. A national prospective study in Italy. Proc 38th Annual Meeting ASH. Blood 88:682a, 1996 (abstr 2717, suppl 1)